Macrocyclic lactone derivatives for the treatment of cancer
The present invention provides compounds represented by formula (1): wherein, R 1 , R 2 , R 3 and R 4 are as defined in the specification, in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable polymorphs and prodrugs. The invention also relates to processes for the manufacture of compounds of formula (1) and pharmaceutical compositions containing them. The compounds and the pharmaceutical compositions of the present invention are useful for the treatment of cancer. The present invention further provides a method of treatment of cancer by administering a therapeutically effective amount of the said compound of formula (1) or its pharmaceutical composition, to a mammal in need thereof.
1. A compound of formula (1) having a stereochemical configuration of concanamycin, or a pharmaceutically acceptable salt thereof,
wherein
R1 is hydroxy or alkoxy;
R2 is hydrogen;
R3 is methyl;
R4 is selected from the following formulae:
* indicates point of attachment;
R5 is hydroxy;
R6 is hydrogen;
R7 is hydrogen;
R8 is hydroxy;
R9 is selected from hydroxy, alkyl, alkoxy, aryl, aralkyl, aryloxy, benzyloxy, heterocyclyl, —O-heterocyclyl, —OCH2COOR17 and —OCH2COR18;
R10 is hydroxy;
R11 is hydrogen;
R12 is hydroxy;
R17 is hydrogen or alkyl;
R18 is selected from alkyl, —NHCH2R20, aryl and heterocyclyl; and
R20 is selected from hydrogen, alkyl, aryl and heterocyclyl;
where alkyl is unsubstituted or substituted by one or two of the same or different groups selected from: hydroxy, halogen, amino, hydroxyalkyl, alkoxy, aryl, aryloxy and heterocyclyl;
alkoxy is unsubstituted or substituted by one or two of the same or different groups selected from: halogen, hydroxy, alkyl and hydroxyalkyl;
aryl is unsubstituted or substituted by one or two of the same or different groups selected from: halogen, hydroxy, amino, alkyl, hydroxyalkyl, alkoxy, aryl and heterocyclyl;
heterocyclyl is unsubstituted or substituted by one or two of the same or different groups selected from: halogen, hydroxy, amino, alkyl, hydroxyalkyl, alkoxy, aryl and heterocyclyl.
2. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein
R1 is hydroxy or alkoxy;
R2 is hydrogen;
R3 is methyl;
R4 is selected from the following formulae:
and
* indicates point of attachment;
R8 is hydroxy;
R9 is selected from hydroxy, alkyl, alkoxy, aryl, aralkyl, aryloxy, benzyloxy, heterocyclyl, —O-heterocyclyl, —OCH2COOR17 and —OCH2COR18;
R10 is hydroxy;
R11 is hydrogen
R12 is hydroxy;
R17 is hydrogen or alkyl;
R18 is selected from alkyl, —NHCH2R20, aryl and heterocyclyl; and
R20 is selected from hydrogen, alkyl, aryl, and heterocyclyl;
where alkyl is unsubstituted or substituted by one or two of the same or different groups selected from: hydroxy, halogen, amino, hydroxyalkyl, alkoxy, aryl, aryloxy and heterocyclyl;
alkoxy is unsubstituted or substituted by one or two of the same or different groups selected from: halogen, hydroxy, alkyl and hydroxyalkyl;
aryl is unsubstituted or substituted by one or two of the same or different groups selected from: halogen, hydroxy, amino, alkyl, hydroxyalkyl, alkoxy, aryl and heterocyclyl;
heterocyclyl is unsubstituted or substituted by one or two of the same or different groups selected from: halogen, hydroxy, amino, alkyl, hydroxyalkyl, alkoxy, aryl and heterocyclyl.
3. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein
R1 is hydroxy;
R2 is hydrogen;
R3 is methyl;
R4 is formula (3):
* indicates point of attachment;
R8 is hydroxy; and
R9 is selected from hydroxy, alkyl, alkoxy and benzyloxy;
where alkyl is unsubstituted or substituted by one or two of the same or different groups selected from: hydroxy, halogen, amino, hydroxyalkyl and alkoxy.
4. A compound according to claim 3 , or a pharmaceutically acceptable salt thereof, wherein
R1 is hydroxy;
R2 is hydrogen;
R3 is methyl;
R4 is formula (3):
* indicates point of attachment;
R8 is hydroxy; and
R9 is selected from hydroxy, methoxy and benzyloxy.
5. A compound according to claim 4 , or a pharmaceutically acceptable salt thereof, wherein
R1 is hydroxy;
R2 is hydrogen;
R3 is methyl;
R4 is formula (3):
* indicates point of attachment;
R8 is hydroxy; and
R9 is hydroxy.
6. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein
R1 is hydroxy or alkoxy;
R2 is hydrogen;
R3 is methyl;
R4 is formula (3):
* indicates point of attachment;
R8 is hydroxy;
R9 is —OCH2COOR17 or —OCH2COR18;
R17 is hydrogen or alkyl;
R18 is selected from alkyl, heterocyclyl and —NHCH2R20; and
R20 is selected from hydrogen, alkyl, aryl and heterocyclyl;
where alkyl is unsubstituted or substituted by one or two of the same or different groups selected from: hydroxy, halogen, amino, hydroxyalkyl and alkoxy;
alkoxy is unsubstituted or substituted by one or two of the same or different groups selected from: hydroxy, alkyl and hydroxyalkyl;
aryl is unsubstituted or substituted by one or two of the same or different groups selected from: halogen, hydroxy, hydroxyalkyl, alkoxy, aryl and heterocyclyl;
heterocyclyl is unsubstituted or substituted by one or two of the same or different groups selected from: hydroxy, hydroxyalkyl, alkyl, alkoxy, aryl and heterocyclyl.
7. A compound according to claim 6 , or a pharmaceutically acceptable salt thereof, wherein
R1 is hydroxy;
R2 is hydrogen;
R3 is methyl;
R4 is formula (3):
* indicates point of attachment;
R8 is hydroxy;
R9 is —OCH2COOR17; and
R17 is hydrogen or alkyl.
8. A compound according to claim 6 , or a pharmaceutically acceptable salt thereof, wherein
R1 is hydroxy;
R2 is hydrogen;
R3 is methyl;
R4 is formula (3):
* indicates point of attachment;
R8 is hydroxy;
R9 is —OCH2COR18; and
R18 is selected from 4-methylpiperazin-1-yl, piperidin-1-yl and 1,4′-bipiperidin-1′-yl.
9. A compound according to claim 6 , or a pharmaceutically acceptable salt thereof, wherein
R1 is hydroxy;
R2 is hydrogen;
R3 is methyl;
R4 is formula (3):
* indicates point of attachment;
R8 is hydroxy;
R9 is —OCH2COR18;
R18 is —NHCH2R20; and
R20 is alkyl or aryl;
where alkyl is unsubstituted or substituted by one or two of the same or different groups selected from: hydroxy, halogen, amino, hydroxyalkyl and alkoxy;
aryl is unsubstituted or substituted by one or two of the same or different groups selected from: halogen, hydroxy and alkoxy.
10. A compound according to claim 9 , or a pharmaceutically acceptable salt thereof, wherein
R1 is hydroxy;
R2 is hydrogen;
R3 is methyl;
R4 is formula (3):
* indicates point of attachment;
R8 is hydroxy;
R9 is —OCH2COR18;
R18 is —NHCH2R20; and
R20 is —CH2OH or 4-fluorophenyl.
11. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein
R1 is hydroxy or alkoxy;
R2 is hydrogen;
R3 is methyl;
R4 is formula (6):
* indicates point of attachment;
R10 is hydroxy.
12. A compound according to claim 11 , or a pharmaceutically acceptable salt thereof, wherein
R1 is hydroxy;
R2 is hydrogen;
R3 is methyl;
R4 is formula (6):
* indicates point of attachment;
R10 is hydroxy.
13. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein
R1 is hydroxy or alkoxy;
R2 is hydrogen;
R3 is methyl;
R4 is formula (7):
* indicates point of attachment;
R10 is hydroxy;
R11 is hydrogen; and
R12 is hydroxy.
14. A compound according to claim 13 , or a pharmaceutically acceptable salt thereof, wherein
R1 is hydroxy;
R2 is hydrogen;
R3 is methyl;
R4 is formula (7):
indicates point of attachment;
R10 is hydroxy;
R11 is hydrogen; and
R12 is hydroxy.
15. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is:
16. A pharmaceutical composition, comprising a therapeutically effective amount of one or more compounds of formula (1) according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
17. A method for the treatment of cancer comprising administering to a mammal in need thereof a therapeutically effective amount of one or more compounds of formula (1) according to claim 1 , or a pharmaceutically acceptable salt thereof.